PCVX stock news · Vaxcyte Inc.
Get alerts for PCVX
Follow Vaxcyte Inc. (PCVX) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for PCVXStephen King criticizes Trump’s new press secretary for her old posts about vaccines and election claims.
NeutralThe story mentions Vaxcyte’s recent share rise but reports no new company development or link between the dispute and Vaxcyte’s business.
Stock futures are up today as Scott Bessent pushes for more action on Iran, with OPCH, PCVX, and STZ getting attention.
NeutralVaxcyte announced results from an adult trial, but this story does not say what the results showed. Without those findings, it does not establish a change in the company's outlook.
Moderna, Vaxcyte, and Novavax are getting attention after a possible pneumonic plague case in Russia worries people.
NeutralVaxcyte announced a $1 billion raise to fund trials, manufacturing and launch work. The plan also brings new shares, warrants and debt, so the funding and added financing balance here.
12 health care stocks are changing a lot during Monday's trading.
NeutralVaxcyte shares rose 30.48% during Monday’s session, but the story gives no reason or company update. The price move alone does not change its business outlook.
12 health care companies saw big changes during Monday's trading.
NeutralVaxcyte's shares rose 30% on Monday. The story gives no company news to show that its business prospects changed.
The Dow went up by 100 points, but the ISM Services PMI dropped in September.
Good for PCVXVaxcyte reported positive results from a late-stage VAX-31 study. This supports its vaccine program, though the report gives no final results or approval.
12 health care companies are changing in price before the market opens on Monday.
NeutralVaxcyte shares rose 54.92% before Monday's open, but the story gives no company news explaining the move. It does not change the picture of Vaxcyte's business.
Vaxcyte, Inc. shares important news about its vaccine trial results.
Good for PCVXVaxcyte reported positive top-line results from a Phase 3 adult trial of VAX-31. This supports the candidate's progress, though the filing gives no result figures or approval.